Cancer of Unknown Primary Finally Revealed to Be a Metastatic Prostate Cancer: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The vast majority of patients with metastatic prostate cancer present with bone metastases and high prostate specific antigen (PSA) level. Rarely, prostate cancer can develop in patients with normal PSA level. Here, we report a patient who presented with a periureteral tumor of unknown primary site that was confirmed as prostate adenocarcinoma after three years with using specific immunohistochemical examination. A 64-year old man was admitted to our hospital with left flank pain associated with masses on the left pelvic cavity with left hydronephrosis. All tumor markers including CEA, CA19-9, and PSA were within the normal range. After an exploratory mass excision and left nephrectomy, the pelvic mass was diagnosed as poorly differentiated carcinoma without specific positive immunohistochemical markers. At that time, we treated him as having a cancer of unknown primary site. After approximately three years later, he revisited the hospital with a complaint of right shoulder pain. A right scapular mass was newly detected with a high serum PSA level (101.7 ng/ml). Tissues from the scapular mass and prostate revealed prostate cancer with positive immunoreactivity for P504S, a new prostate cancer-specific gene. The histological findings were the same as the previous pelvic mass; however, positive staining for PSA was observed only in the prostate mass. This case demonstrates a patient with prostate cancer and negative serological test and tissue staining that turned out to be positive during progression. We suggest the usefulness of newly developed immunohistochemical markers such as P504S to determine the specific primary site of metastatic poorly differentiated adenocarcinoma in men.
Abstract
The vast majority of patients with metastatic prostate cancer present with bone metastases and high prostate specific antigen (PSA) level. Rarely, prostate cancer can develop in patients with normal PSA level. Here, we report a patient who presented with a periureteral tumor of unknown primary site that was confirmed as prostate adenocarcinoma after three years with using specific immunohistochemical examination. A 64-year old man was admitted to our hospital with left flank pain associated with masses on the left pelvic cavity with left hydronephrosis. All tumor markers including CEA, CA19-9, and PSA were within the normal range. After an exploratory mass excision and left nephrectomy, the pelvic mass was diagnosed as poorly differentiated carcinoma without specific positive immunohistochemical markers. At that time, we treated him as having a cancer of unknown primary site. After approximately three years later, he revisited the hospital with a complaint of right shoulder pain. A right scapular mass was newly detected with a high serum PSA level (101.7 ng/ml). Tissues from the scapular mass and prostate revealed prostate cancer with positive immunoreactivity for P504S, a new prostate cancer-specific gene. The histological findings were the same as the previous pelvic mass; however, positive staining for PSA was observed only in the prostate mass. This case demonstrates a patient with prostate cancer and negative serological test and tissue staining that turned out to be positive during progression. We suggest the usefulness of newly developed immunohistochemical markers such as P504S to determine the specific primary site of metastatic poorly differentiated adenocarcinoma in men.
참고문헌 (14)
- Pavlidis N, "Diagnostic and therapeutic management of cancer of an unknown primary", Eur J Cancer, 39, pp.1990~2005 (2003)
- Annual report of the cause of death in Korea 2006, , Ministry of health and welfare, Central cancer registry center, regional cancer registry, ~
- Varadhachary GR, "Diagnostic strategies for unknown primary cancer", Cancer, 100, pp.1776~1785 (2004)
- Greco FA, "Cancer of unknown primary site, in Cancer: principles and practice of oncology, 7th ed", pp.2213~2236 (2005), Lippincott
- Polascik TJ, "Prostate specific antigen: a decade of discovery: what we have learned and where we are going", J Urol, 162, pp.293~306 (1999)
- Thompson IM, "Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter", N Engl J Med, 350, pp.2239~2246 (2004)
- Goldstein NS, "Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores", Am J Clin Pathol, 117, pp.471~477 (2002)
- Sheridan T, "The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate", Am J Surg Pathol, 31, pp.1351~1355 (2007)
- Xu J, "Identification of differentially expressed genes in human prostate cancer using subtraction and microarray", Cancer Res, 60, pp.1677~1682 (2000)
- Jiang Z, "P504S: a new molecular marker for the detection of prostate carcinoma", Am J Surg Pathol, 25, pp.1397~1404 (2001)
- Rubin MA, "Methylacyl Coenzyme A Racemase as a tissue biomarker for prostate cancer", JAMA, 287, pp.1662~1670 (2002)
- Beach R, "P504S immunohistochemical detection in 405 prostatic specimens including 376 18- gauge needle biopsies", Am J Surg Pathol, 26, pp.1588~1596 (2002)
- Chuang AY, "Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma", Am J Surg Pathol, 31, pp.1246~1255 (2007)
- Martínez-Rodríguez M, "Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases", Int J Surg Pathol, 15, pp.213~218 (2007)